What Actually Happens When You Try to Build a Medical Device from Scratch
Most people who hear about Richard Shulman Medical Technologies Group never realize the kind of friction is involved in turning a clinical idea into something the FDA will actually approve. The company has built its reputation on bridging the gap between raw engineering concepts and the regulatory realities that kill most projects before they ship. I have sat through enough design review meetings to recognize when a team is pretending the pathway is simple, and it rarely is. There is a specific workflow pattern that separates companies that ship regulated products from ones that stall at 510(k) submission. Richard Shulman Medical Technologies Group tends to organize around that workflow rather than around isolated invention days. The process starts with problem scoping, moves into design control documentation, then hits verification and validation testing, and finally arrives at regulatory strategy. Most people jump straight to prototyping. That is where everything goes wrong. I spent time reviewing files for a group developing a wearable monitoring sensor, and the core issue was not the sensor itself. It was the lack of an initial intended use statement that matched the clinical indication. The team had built a device that could technically measure heart rate variability, but their regulatory pathway assumed a therapeutic claim that required much stricter clinical evidence. We restructured the labeling language and redefined the intended use to stay within the predicate device space. The device shipped three months later instead of getting stuck in a prolonged pre-submission loop.
Design Controls Are Not Paperwork. They Are Liability Defense.
Medical device development requires a formal design history file, or DHF, from the moment you start defining requirements. I do not say this to sound dramatic. I say it because reviewers will reject a submission if the traceability between user needs, design inputs, and design outputs is missing or inconsistent. A single mismatch between a requirement document and a test report can trigger a deficiency letter that delays approval by six to nine months. One thing beginners miss about design controls is that they are not sequential. You revisit them constantly. When a risk analysis uncovers a new failure mode, you update the design input, which may require a design change, which triggers a new verification test, which may adjust your validation plan. The documentation has to track every iteration. Richard Shulman Medical Technologies Group handles this by maintaining living requirement matrices that auto-link changes across documents. It reduces the chance of orphaned requirements, which is one of the most common causes of submission rejection.
The Verification and Validation Trap
Verification asks whether you built the device right. Validation asks whether you built the right device. These sound simple but most teams conflate them during the build phase. I once saw a project where the engineering team treated bench-level electrical testing as validation for a patient-facing product. The device passed all internal checks but failed clinical usability testing because the interface assumed a trained user. Regulators caught the gap during review. The fix required a full redesign of the user interface and a repeat of validation protocols. That delay cost roughly four months and significant budget. Validation testing should involve actual end users in environments close to real use conditions. Not simulated lab conditions, not ideal lab environments, but conditions that resemble what happens when a busy nurse or a patient at home interacts with the product. This is where many early-stage companies underestimate the effort required. They assume a small user study is enough. It is not enough if the device carries any diagnostic or therapeutic risk.
Get the Full Details
Regulatory Strategy Determines Timeline More Than Engineering Does
The biggest mistake I see is teams letting engineers choose the regulatory pathway after development is mostly complete. By that point, the architecture may not support the evidence required for a 510(k), and the alternative is a De Novo or PMA, which can take years. Richard Shulman Medical Technologies Group tends to front-load regulatory strategy, often before detailed engineering begins. This means defining the predicate device, mapping the regulatory pathway, and identifying gaps early. A counter-intuitive point here is that a 510(k) is not automatically the fastest route. If your device lacks a sufficiently similar predicate or introduces new technological characteristics, the FDA may request a De Novo classification instead, which can take longer than a straight PMA in some cases. I learned this when a team thought they were pursuing a standard 510(k) and ended up spending eight months in a regulatory classification queue because their device used a novel sensor modality that reviewers could not map to existing predicates.
Software as a Medical Device Adds a Whole Other Layer
If the product includes any software that diagnoses, monitors, or treats a condition, it falls under SaMD guidelines. The FDA expects software documentation that covers version control, algorithm validation, cybersecurity planning, and post-market monitoring. I find that many hardware-focused teams treat software as an afterthought, which is a costly mistake. Cybersecurity alone can trigger a complete review cycle if the device connects to a network and lacks an acceptable plan. One workaround I rely on is treating the software development lifecycle as a separate but linked workstream. This means maintaining parallel design histories for hardware and software while ensuring traceability between them. It adds documentation overhead, but it prevents the kind of integration failures that show up during regulatory review. Richard Shulman Medical Technologies Group uses this split-workstream model on most projects involving embedded software.
Realistic Downsides Worth Noting
No development framework is perfect. The design control approach creates a heavier documentation burden, especially for smaller teams. There is a real trade-off between speed and thoroughness, and some teams cut corners on documentation to meet aggressive launch dates. That usually comes back during submission. Another limitation is that regulatory pathways shift over time. The FDA issues new guidance documents regularly, and what was acceptable two years ago may not be acceptable now. Teams must stay current, and that requires dedicated regulatory intelligence resources. If you are considering working with a firm like Richard Shulman Medical Technologies Group, expect a process that prioritizes regulatory readiness over rapid prototyping. It slows early iteration but prevents expensive setbacks later. For teams that move too fast in the beginning, the regulatory review phase becomes the bottleneck, and that is where most projects stall permanently.
